Publications by authors named "Lisa D Eli"

Claim this Profile
E
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Elisabeth Quoix, Lisa D Eli

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 breast cancer that limits trastuzumab deruxtecan efficacy.
Dong Hu, Xiaoshuang Lyu, Zheqi Li, Prasanna Ekambaram, Anushka Dongre, Felicia Kemp, Lisa D Eli

Nat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial.
Jonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, Komal Jhaveri, Maria de Miguel, Lisa D Eli

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A Piha-Paul, Joseph S Light, Albert S Cornelius, Lisa D Eli

Liver Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.
Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Lisa D Eli

Transl Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Claire F Friedman, Anishka D'Souza, Diana Bello Roufai, Anna V Tinker, Maria de Miguel, Michelle E Melisko, Lisa D Eli

Gynecol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Lisa D Eli

Nat Commun· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of neratinib resistance in -mutant metastatic breast cancer.
Lisa D Eli, Shyam M Kavuri

Cancer Drug Resist· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
Michele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M Hyman, Natalie Blauvelt, Lisa D Eli

Clin Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M Brufksy, Lisa D Eli

Clin Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Lisa D Eli

Biomedicines· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Neil T Conlon, Jeffrey J Kooijman, Suzanne J C van Gerwen, Winfried R Mulder, Guido J R Zaman, Lisa D Eli

Br J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Ana Oaknin, Claire F Friedman, Lynda D Roman, Anishka D'Souza, Irene Brana, Lisa D Eli

Gynecol Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer.
Lillian M Smyth, Sarina A Piha-Paul, Helen H Won, Alison M Schram, Cristina Saura, Alexander N Gorelick, Lisa D Eli

Cancer Discov· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and -Mutated Breast Cancer.
Denis M Collins, Neil T Conlon, Srinivasaraghavan Kannan, Chandra S Verma, Lisa D Eli

Cancers (Basel)· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Stephen K L Chia, Miguel Martin, Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge, Neelima Denduluri, Lisa D Eli

Breast Cancer Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M Hyman, Sarina A Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Lisa D Eli

Nature· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M Hyman, Sarina A Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Lisa D Eli

Nature· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis